{{Drugbox
| IUPAC_name =   1-(1-(2-fluorophenyl)-2-phenylethyl)pyrrolidine
| image = Fluorolintane_structure.png

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number =
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 

|  ChemSpiderID = 58838621

<!--Chemical data-->
| C=18 | H=20 | F=1 | N=1
| molecular_weight =
| melting_point =
| smiles            = FC1=C(C=CC=C1)C(CC2=CC=CC=C2)N3CCCC3
| StdInChI          = 1S/C18H20FN/c19-17-11-5-4-10-16(17)18(20-12-6-7-13-20)14-15-8-2-1-3-9-15/h1-5,8-11,18H,6-7,12-14H2
| StdInChIKey       = ZAGWVXYVNFPCLW-UHFFFAOYSA-N
}}

'''Fluorolintane''' (also known as '''2-FPPP''') is a [[Dissociative drug|dissociative]] [[anesthesia|anesthetic]] drug that has been sold online as a [[designer drug]].<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1689/abstract | title=Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers |author1=Jason Wallach |author2=Pierce V. Kavanagh |author3=Gavin McLaughlin |author4=Noreen Morris |author5=John D. Power |author6=Simon P. Elliott |author7=Marion S. Mercier |author8=David Lodge |author9=Hamilton Morris |author10=Nicola M. Dempster |author11=Simon D. Brandt | journal=Drug Testing and Analysis |date=May 2014  | volume=7 | issue=5 | pages=358–367 | doi=10.1002/dta.1689 | pmid=25044512}}</ref><ref>{{cite web | url=http://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/FLUOROLINTANE-ID-1420-15-report_final.pdf | title=Analytical Report - Fluorolintane | publisher=Nacionalni forenzični laboratorij (NFL) | date=January 2016}}</ref>

Fluorolintane and related diarylethylamines are [[Receptor antagonist|antagonists]] of the [[NMDA receptor]]<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0968089609002624 | title=NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds |author1=Michael L. Berger |author2=Anna Schweifer |author3=Patrick Rebernik |author4=Friedrich Hammerschmidt | journal=Bioorganic & Medicinal Chemistry |date=May 2009  | volume=17 | issue=1 | pages=3456–3462 | doi=10.1016/j.bmc.2009.03.025 | pmid=19345586}}</ref> and have been studied ''[[in vitro]]'' as potential treatments for [[Neurotoxicity|neurotoxic]] injury,<ref>{{cite web | url=https://www.google.com/patents/EP0346791B1 | title=Patent EP 0346791 B1 - 1,2-diarylethylamines for treatment of neurotoxic injury | accessdate=17 June 2015 |author1=Nancy M. Gray |author2=Brian K. Cheng }}</ref> [[Depression (mood)|depression]]<ref>{{cite web | url=https://www.google.com/patents/US3083139 | title=Patent US 3083139 A - Therapeutic 1-(1, 2-diphenylethyl) pyrrolidine for the management of depression | date=1963 | accessdate=22 June 2015 |author1=Brooke D Aspergren |author2=Richard V Heinzelman }}</ref> and as [[Sympathomimetic drug|sympathomimetic]].<ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/ja01110a033 | title=Compounds Containing the Pyrrolidine Ring. Analogs of Sympathomimetic Amines |author1=R. V. Heinzelman |author2=B. D. Aspergren | journal=Journal of the American Chemical Society  |date=July 1953  | volume=75 | issue=14 | pages=3409–3413 | doi=10.1021/ja01110a033}}</ref>

==See also==
* [[AD-1211]]
* [[Diphenidine]]
* [[Ephenidine]]
* [[Lanicemine]]
* [[Methoxphenidine]] (MXP)
* [[MT-45]]
* [[Prolintane]]
* [[Remacemide]]

==References==
{{Reflist|2}}

{{Ionotropic glutamate receptor modulators}}

[[Category:Designer drugs]]
[[Category:Dissociative drugs]]
[[Category:NMDA receptor antagonists]]
[[Category:Diarylethylamines]]
[[Category:Fluoroarenes]]
[[Category:Pyrrolidines]]


{{nervous-system-drug-stub}}